BRPI0916186A2 - vacinas de idna e métodos para uso das mesma - Google Patents

vacinas de idna e métodos para uso das mesma

Info

Publication number
BRPI0916186A2
BRPI0916186A2 BRPI0916186A BRPI0916186A BRPI0916186A2 BR PI0916186 A2 BRPI0916186 A2 BR PI0916186A2 BR PI0916186 A BRPI0916186 A BR PI0916186A BR PI0916186 A BRPI0916186 A BR PI0916186A BR PI0916186 A2 BRPI0916186 A2 BR PI0916186A2
Authority
BR
Brazil
Prior art keywords
methods
idna
vaccines
idna vaccines
Prior art date
Application number
BRPI0916186A
Other languages
English (en)
Inventor
Lukashevich Igor
M Pushko Peter
Original Assignee
Medigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigen Inc filed Critical Medigen Inc
Publication of BRPI0916186A2 publication Critical patent/BRPI0916186A2/pt
Publication of BRPI0916186B1 publication Critical patent/BRPI0916186B1/pt
Publication of BRPI0916186B8 publication Critical patent/BRPI0916186B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/193—Equine encephalomyelitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0916186A 2008-07-17 2009-07-17 vetor de plasmídeo e seu uso, vacina para febre amarela e para vírus de rna infeccioso e vírus atenuado vivo clonalmente purificado homogêneo e seu uso BRPI0916186B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8148208P 2008-07-17 2008-07-17
US61/081,482 2008-07-17
PCT/US2009/004133 WO2010008576A2 (en) 2008-07-17 2009-07-17 Idna vaccines and methods for using the same

Publications (3)

Publication Number Publication Date
BRPI0916186A2 true BRPI0916186A2 (pt) 2018-05-29
BRPI0916186B1 BRPI0916186B1 (pt) 2021-03-09
BRPI0916186B8 BRPI0916186B8 (pt) 2021-05-25

Family

ID=41550920

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916186A BRPI0916186B8 (pt) 2008-07-17 2009-07-17 vetor de plasmídeo e seu uso, vacina para febre amarela e para vírus de rna infeccioso e vírus atenuado vivo clonalmente purificado homogêneo e seu uso

Country Status (6)

Country Link
US (3) US8691563B2 (pt)
EP (3) EP3992296A1 (pt)
BR (1) BRPI0916186B8 (pt)
DK (2) DK2977457T3 (pt)
ES (2) ES2544702T3 (pt)
WO (1) WO2010008576A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2544702T3 (es) * 2008-07-17 2015-09-02 Medigen, Inc. Vacunas en forma de ADNi y métodos para utilizarlas
US10602508B2 (en) * 2015-08-10 2020-03-24 Qualcomm Incorporated LTE-direct communication for vehicle-to-vehicle
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
ATE276271T1 (de) * 1998-03-27 2004-10-15 Secr Defence Rekombinantes virus
FR2779736B1 (fr) 1998-06-12 2002-12-13 Goemar Lab Sa Genes codant pour des beta-agarases et leur utilisation pour la production d'enzymes de biodegradation des agars
CA2354374A1 (en) * 1998-12-07 2000-06-15 U.S. Medical Research Institute Of Infectious Diseases Live attenuated venezuelan equine encephalitis vaccine
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
JP4608210B2 (ja) * 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアルファウイルスレプリコン粒子
AU2003902842A0 (en) 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
WO2005026316A2 (en) * 2003-09-15 2005-03-24 Bioption Ab Alphavirus vaccines
US7459163B2 (en) 2004-02-25 2008-12-02 University Of Kansas Infectious DNA as a vaccine against west nile and other flaviviruses
US20060198854A1 (en) 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
ES2544702T3 (es) * 2008-07-17 2015-09-02 Medigen, Inc. Vacunas en forma de ADNi y métodos para utilizarlas
ES2647662T3 (es) * 2009-12-31 2017-12-26 Medigen, Inc. Vacunas de ADN infeccioso frente al virus chikungunya

Also Published As

Publication number Publication date
WO2010008576A3 (en) 2010-04-29
US9968672B2 (en) 2018-05-15
HK1220720A1 (en) 2017-05-12
US20180243404A1 (en) 2018-08-30
ES2902787T3 (es) 2022-03-29
US20140178430A1 (en) 2014-06-26
BRPI0916186B8 (pt) 2021-05-25
EP2310510B1 (en) 2015-05-06
WO2010008576A2 (en) 2010-01-21
BRPI0916186B1 (pt) 2021-03-09
US20110243989A1 (en) 2011-10-06
US10653769B2 (en) 2020-05-19
US8691563B2 (en) 2014-04-08
EP3992296A1 (en) 2022-05-04
EP2977457A3 (en) 2016-05-04
DK2310510T3 (en) 2015-08-03
EP2977457B1 (en) 2021-09-01
EP2310510A2 (en) 2011-04-20
EP2310510A4 (en) 2012-01-25
ES2544702T3 (es) 2015-09-02
DK2977457T3 (da) 2021-12-06
EP2977457A2 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
BRPI0911297A2 (pt) composição e métodos para preparo e uso das mesmas
BRPI0820556A2 (pt) Bactéria e métodos para uso das mesmas
BRPI0920891A2 (pt) misturas de alfa-amilase e métodos para uso das referidas misturas
BRPI1013432A2 (pt) derivado de indolizina e uso do mesmo para propósitos médicos
BRPI0912703A2 (pt) composições imuno-moduladoras e métodos para uso dessas
BRPI0809600A2 (pt) vírus atenuado útil para vacinas
BR112012004807A2 (pt) vacina para pcsk9
PT2427212T (pt) Anticorpos anti-cd100 e métodos para utilização dos mesmos
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0816063A2 (pt) Garrafas retráteis e métodos para uso do mesmo
BR112012031232A2 (pt) método, dispositivo e uso
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0914034A2 (pt) dispositivo para limpeza de piso e método de limpeza de um piso
BRPI0818056A2 (pt) Aparelho e métodos para hemodiálise
BR112012005807A2 (pt) materiais expansíveis e mpetodos para uso
BR112012003445A2 (pt) aparelho dental sem o uso das maos para limpeza dos dentes
BRPI0821668A2 (pt) Uso
UY33132A (es) Proteínas solubles para su uso terapéutico
BRPI0817299A2 (pt) Vacinas e componentes de vacina para inibição de células microbianas
BR112013010272A2 (pt) métodos analíticos e arranjos para uso nos mesmos
BRPI0816318A2 (pt) Dispositivo de liberação transdérmica, e, método para preparar o mesmo
BRPI1012638A2 (pt) métodos e intermediários para preparar agentes farmacêuticos
PT2868315T (pt) Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BRPI0817179A2 (pt) Dispositivo para aeronave motorizada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF